Agennix AG Announces U.S. Class Action Lawsuit Against Predecessor GPC Biotech AG Fully Closed
(Thomson Reuters ONE) - Agennix AG / Agennix AG Announces U.S. Class Action Lawsuit Against Predecessor GPC Biotech AG Fully Closed processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. - Court rejects request to file amended complaint and reaffirms dismissal of case with prejudice -Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, February 10, 2010 -Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the class actionlawsuit brought against its predecessor, GPC Biotech AG, in the United StatesDistrict Court for the Southern District of New York, is now fully closed.In March 2009, the Court issued an order dismissing the consolidated classaction complaint against GPC Biotech in the action that was commenced in July2007. Pursuant to that order, the plaintiffs were given the opportunity to filea motion seeking permission of the Court to file an amended consolidated classaction complaint. The plaintiffs subsequently filed this motion with the Courtand the Company opposed the request. On December 29, 2009 the Court issued adecision denying the plaintiff's request to file an amended complaint andordered that judgment be entered dismissing the complaint in accordance with theCourt's decision of March 12, 2009, with prejudice. The period to file anappeal to that decision has now expired and the case is fully closed.About AgennixAgennix AG is a publicly traded biopharmaceutical company that is developingnovel therapies in areas of major unmet medical need to improve the length andquality of life of seriously ill patients. The Company's most advanced programis talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials innon-small cell lung cancer. Agennix also has recently reported positive resultsfrom a Phase 2 trial evaluating talactoferrin in severe sepsis. Other clinicaldevelopment programs include RGB-286638, a multi-targeted kinase inhibitor inPhase 1 testing; the oral platinum-based compound satraplatin; and a topical gelform of talactoferrin for diabetic foot ulcers. Agennix's registered seat is inHeidelberg, Germany. The Company has three sites of operation:Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. Foradditional information, please visit the Agennix Web site at www.agennix.com.This press release contains forward-looking statements, which express thecurrent beliefs and expectations of the management of Agennix AG. Suchstatements are based on current expectations and are subject to risks anduncertainties, many of which are beyond our control, that could cause futureresults, performance or achievements to differ significantly from the results,performance or achievements expressed or implied by such forward-lookingstatements. Actual results could differ materially depending on a number offactors, and we caution investors not to place undue reliance on theforward-looking statements contained in this press release. Forward-lookingstatements speak only as of the date on which they are made and Agennixundertakes no obligation to update these forward-looking statements, even if newinformation becomes available in the future.For further information, please contact:AgennixAGInvestor Relations & Corporate CommunicationsPhone: +49 (0)89 8565 2693ir(at)agennix.com
Datum: 10.02.2010 - 09:58 Uhr
Sprache: Deutsch
News-ID 12278
Anzahl Zeichen: 0
contact information:
Town:
Martinsried
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 282 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Agennix AG Announces U.S. Class Action Lawsuit Against Predecessor GPC Biotech AG Fully Closed"
steht unter der journalistisch-redaktionellen Verantwortung von
Agennix AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
